Of the other drugs with largely overlapping abilities to inhibit VEGFR, PDGFR and FGFR signaling, regorafenib, at least as a single agent, seems to be an interesting option given its reported responses in both OS and ES patients. This evidence concerns the gene KDR and Ewing sarcoma.